Alx Oncology Holdings (ALXO) Capital Expenditures (2019 - 2026)
Alx Oncology Holdings (ALXO) reported Capital Expenditures of $50000.0 for Q1 2026, down 16.67% on a YoY basis from $60000.0 in Q1 2025, and up 2.04% sequentially from $49000.0 in Q4 2025.
Alx Oncology Holdings (ALXO) Capital Expenditures (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of Capital Expenditures data on file, last reported at $50000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 16.67% year-over-year to $50000.0; the trailing twelve-month figure through Mar 2026 stood at $202000.0 (down 43.73% YoY), and the FY2025 full-year result was $212000.0, down 52.57% from the prior year.
- Capital Expenditures climbed to $50000.0 in Q1 2026, from $49000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q2 2023 to a low of -$1.3 million in Q3 2023.
- A 5-year average of $200588.2 and a median of $90000.0 in 2024 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures surged 8314.29% in 2022 and slumped 4443.33% in 2023, its largest moves.
- Tracing ALXO's Capital Expenditures over 5 years: stood at $551000.0 in 2022, then slumped by 73.14% to $148000.0 in 2023, then plunged by 59.46% to $60000.0 in 2024, then slipped by 18.33% to $49000.0 in 2025, then rose by 2.04% to $50000.0 in 2026.
- Business Quant data shows ALXO's Capital Expenditures at $50000.0 in Q1 2026, $49000.0 in Q4 2025, and $56000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | 50,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50,000.00 |
| Mar 31, 2026 | 50,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 149,000.00 |
| Sep 30, 2024 | 149,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |